Parallel Advisors’s TherapeuticsMD TXMD Stock Holding History

Parallel Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-21	Closed	-$3K	–	2492
2019 Q2	$3K	Hold	21	–	–	﹤0.01%	2023
2019 Q1	$5K	Hold	21	–	–	﹤0.01%	1809
2018 Q4	$3K	Hold	21	–	–	﹤0.01%	1794
2018 Q3	$7K	Hold	21	–	–	﹤0.01%	1604
2018 Q2	$6K	Sell	21 -8	-28%	-$2.44K	﹤0.01%	1558
2018 Q1	$7K	Hold	29	–	–	﹤0.01%	1435
2017 Q4	$9K	Hold	29	–	–	﹤0.01%	1355
2017 Q3	$9K	Hold	29	–	–	﹤0.01%	1341
2017 Q2	$8K	Hold	29	–	–	﹤0.01%	1407
2017 Q1	$7K	Buy	+29	New	+$8.97K	﹤0.01%	1371

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's TXMD Position: Q3 2019 in Review

Parallel Advisors sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 21 shares — an estimated $3K sold.

Parallel Advisors first reported a position in TXMD in Q1 2017 and held it in 10 quarters. The position peaked at $9K in Q4 2017. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

Parallel Advisors reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
Parallel Advisors sold 21 TherapeuticsMD shares in Q3 2019, an estimated $3K.
Parallel Advisors first reported a position in TherapeuticsMD in Q1 2017 and held it in 10 quarters.
Parallel Advisors's TherapeuticsMD position peaked at $9K in Q4 2017.
150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Parallel Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.